Berger Montague PC Announces Class Action Filed Against Novo Nordisk A/S (NYSE: NVO) for Alleged Securities Violations

Core Viewpoint - Berger Montague PC is investigating claims against Novo Nordisk A/S following a class action lawsuit related to federal securities laws [1] Group 1: Legal Action - A class action lawsuit has been filed against Novo Nordisk A/S, prompting an investigation by Berger Montague PC [1] - Investors who purchased Novo securities between May 7, 2025, and July 28, 2025, can seek to be appointed as lead plaintiff representative by September 30, 2025 [2] Group 2: Financial Performance - On July 29, 2025, Novo Nordisk lowered its sales and profit guidance for the second half of fiscal 2025 due to persistent use of compounded GLP-1s, slower-than-expected market expansion, and increased competition for Wegovy® and Ozempic® [3] - Following the guidance revision, Novo's stock price fell from $69.00 to $53.94 per share, marking a one-day decline of over 21% [3]